Results 21 to 30 of about 9,980 (152)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China

Frontiers in Cellular and Infection Microbiology, 2021
ObjectivesThe aim of this work was to investigate the activity of ceftazidime–avibactam (CZA) and aztreonam–avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs).MethodsNon-duplicate CROs, including 56 carbapenem ...
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao   +7 more
doaj   +1 more source

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis

Frontiers in Pharmacology, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li, Dan Li, Dan Li, Fan Fei, Hua Yu, Xiangning Huang, Shanshan Long, Hao Zhou, Jie Zhang   +8 more
doaj   +1 more source

The Klebsiella pneumoniae carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam

Antibiotics, 2023
Klebsiella pneumoniae carbapenemase KPC is an important resistance gene that has disseminated globally in response to carbapenem use. It is now being implicated as a resistance determinant in Ceftazidime Avibactam (CAZ-AVI) resistance. Given that CAZ-AVI
Sona Garsevanyan, Miriam Barlow
doaj   +1 more source

The Rapid CarbaLux Combination Test to Uncover Bacterial Resistance and Heteroresistance Prior to Antibiotic Treatment

Diagnostics
Background/Objectives: In this proof-of-concept study, the objective was to evaluate the phenotypic CarbaLux combination rapid test in terms of guiding the therapy of infections caused by multidrug-resistant Gram-negative bacteria with carbapenemase ...
Hans Rudolf Pfaendler, Hans-Ulrich Schmidt   +1 more
doaj   +1 more source

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches

Antibiotics, 2023
In light of rising antimicrobial resistance and a decreasing number of antibiotics with novel modes of action, it is of utmost importance to accelerate development of novel treatment options.
Kashaf Khalid, Katharina Rox
doaj   +1 more source

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools

Frontiers in Microbiology, 2023
IntroductionAntimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative ...
Gil Verschelden, Gil Verschelden, Maxim Noeparast, Anke Stoefs, Eveline Van Honacker, Kristof Vandoorslaer, Laura Vandervore, Margo Olbrecht, Kathleen Van Damme, Thomas Demuyser, Thomas Demuyser, Denis Piérard, Ingrid Wybo   +12 more
doaj   +1 more source

Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. [PDF]

PLoS ONE, 2015
β-Lactamase inhibition is an important clinical strategy in overcoming β-lactamase-mediated resistance to β-lactam antibiotics in Gram negative bacteria.
Nikhil P Krishnan, Nhu Q Nguyen, Krisztina M Papp-Wallace, Robert A Bonomo, Focco van den Akker   +4 more
doaj   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou, Jinqi Zhu, Ge Wu, Xi Kang, Qing Wang, Jie Liu, Yan Jiang   +6 more
wiley   +1 more source

Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam

Microbiology Spectrum
Avibactam (AVI) is a diazabicyclooctane (DBO) β-lactamase inhibitor used clinically in combination with ceftazidime. At concentrations higher than those typically achieved in vivo, it also has broad-spectrum direct antibacterial activity against ...
Michelle Nägeli, Shade Rodriguez, Aimee Iradukunda, Abigail L. Manson, Ashlee M. Earl, Thea Brennan-Krohn   +5 more
doaj   +1 more source